ORIC Pharmaceuticals is a biopharmaceutical company that develops treatments that target the causes of therapeutic resistance.
ORIC Pharmaceuticals has raised $125.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2025.
ORIC Pharmaceuticals's investors include Vivo Capital, New Enterprise Associates, Pfizer, Foresite Capital, The Column Group.
ORIC Pharmaceuticals is headquartered in South San Francisco, United States.
ORIC Pharmaceuticals is a biopharmaceutical company that develops treatments that target the causes of therapeutic resistance.
ORIC Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ORIC Pharmaceuticals — Funding & Investors." VCBacked, May 28, 2025, https://www.vcbacked.co/company/oric-pharmaceuticals. Accessed July 20, 2026.
VCBacked. (2025). ORIC Pharmaceuticals — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/oric-pharmaceuticals
{{cite web |title=ORIC Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/oric-pharmaceuticals |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated